10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q3 2019

Filing Information

Form Type	10-Q
Accession Number	`0001193125-19-287265`
Period End Date	20190930
Filing Date	20191107
Fiscal Year	2019
Fiscal Period	Q3
XBRL Instance	d794789d10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 84 Income Statement 95 Cash Flow Statement 60 Stockholders Equity 31 Comprehensive Income 33

Balance Sheet 84 line items

Line Item	Tag	Value	Unit	Period
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.24B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.78B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.25B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.82B	USD	Point-in-time
Inventories	`InventoryNet`	$4.73B	USD	Point-in-time
Inventories	`InventoryNet`	$4.64B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$899.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$976.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$468.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$416.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$18.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$92.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.79B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$12.54B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$368.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$331.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$731.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$727.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.87B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.64B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$468.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$14.01B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$11.88B	USD	Point-in-time
Goodwill	`Goodwill`	$24.66B	USD	Point-in-time
Goodwill	`Goodwill`	$24.92B	USD	Point-in-time
Total assets	`Assets`	$57.25B	USD	Point-in-time
Total assets	`Assets`	$60.68B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.22B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.13B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.71B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.14B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.85B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.69B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$583.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$870.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.75B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.87B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$820.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$804.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.32B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.11B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$1.46B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.14B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.73B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$2.55B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$23.81B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$26.70B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$394.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$30.57B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$28.21B	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$42.32B	USD	Point-in-time
Total liabilities	`Liabilities`	$44.89B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; September 30, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; September 30, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.29B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.21B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-5.96B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.07B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.37B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.46B	USD	Point-in-time
Treasury shares as of September 30, 2019 and December 31, 2018 106 million ordinary shares	`TreasuryStockValue`	$4.14B	USD	Point-in-time
Treasury shares as of September 30, 2019 and December 31, 2018 106 million ordinary shares	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$14.71B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$13.79B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.13B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.09B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.93B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.13B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$57.25B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$60.68B	USD	Point-in-time

Income Statement 95 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$14.29B	USD	3 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.26B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$12.90B	USD	3 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.53B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.55B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.44B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$7.32B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$7.97B	USD	3 Qtrs
Gross profit	`GrossProfit`	$1.83B	USD	1 Quarter
Gross profit	`GrossProfit`	$1.98B	USD	1 Quarter
Gross profit	`GrossProfit`	$5.58B	USD	3 Qtrs
Gross profit	`GrossProfit`	$6.33B	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$778.00M	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$311.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$240.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$918.00M	USD	3 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$2.12B	USD	3 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$595.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$699.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.91B	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$873.00M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$954.00M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$309.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$285.00M	USD	1 Quarter
Intangible assets impairment	`IntangibleAssetsImpairments`	$519.00M	USD	1 Quarter
Intangible assets impairment	`IntangibleAssetsImpairments`	$177.00M	USD	1 Quarter
Intangible assets impairment	`IntangibleAssetsImpairments`	$1.21B	USD	3 Qtrs
Intangible assets impairment	`IntangibleAssetsImpairments`	$1.25B	USD	3 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	3 Qtrs
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$139.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$263.00M	USD	3 Qtrs
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$160.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$834.00M	USD	3 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.24B	USD	3 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$19.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$1.17B	USD	3 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$468.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$29.00M	USD	3 Qtrs
Other income	`OtherOperatingIncomeExpenseNet`	$334.00M	USD	3 Qtrs
Other income	`OtherOperatingIncomeExpenseNet`	$14.00M	USD	1 Quarter
Other income	`OtherOperatingIncomeExpenseNet`	$35.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-591.00M	USD	3 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$16.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-81.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$1.53B	USD	3 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-635.00M	USD	3 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-211.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-229.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-736.00M	USD	3 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$791.00M	USD	3 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-292.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-1.23B	USD	3 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-213.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-159.00M	USD	3 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-56.00M	USD	3 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-26.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$11.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-10.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-4.00M	USD	1 Quarter
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-76.00M	USD	3 Qtrs
Share in losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-8.00M	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-307.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-1.08B	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$771.00M	USD	3 Qtrs
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$35.00M	USD	3 Qtrs
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$7.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$11.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$33.00M	USD	3 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-208.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$736.00M	USD	3 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-314.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-1.11B	USD	3 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$195.00M	USD	3 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-273.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-314.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.11B	USD	3 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$541.00M	USD	3 Qtrs
Basic	`EarningsPerShareBasic`	$-1.02	USD	3 Qtrs
Basic	`EarningsPerShareBasic`	$-0.29	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.27	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.53	USD	3 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.29	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.53	USD	3 Qtrs
Diluted	`EarningsPerShareDiluted`	$-1.02	USD	3 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.27	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	3 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	3 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	3 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	3 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter

Cash Flow Statement 60 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-307.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-1.08B	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$771.00M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.46B	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.31B	USD	3 Qtrs
Impairment of long-lived assets	`ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill`	$1.30B	USD	3 Qtrs
Impairment of long-lived assets	`ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill`	$1.50B	USD	3 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$784.00M	USD	3 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.52B	USD	3 Qtrs
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-650.00M	USD	3 Qtrs
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-652.00M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$122.00M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$99.00M	USD	3 Qtrs
Net loss (gain) from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-10.00M	USD	3 Qtrs
Net loss (gain) from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$53.00M	USD	3 Qtrs
Other items	`OtherOperatingActivitiesCashFlowStatement`	$5.00M	USD	3 Qtrs
Other items	`OtherOperatingActivitiesCashFlowStatement`	$-8.00M	USD	3 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	3 Qtrs
Impairment of equity investment	`ImpairmentOfInvestments`	$103.00M	USD	3 Qtrs
In process research and development	`ResearchAndDevelopmentExpense`	$54.00M	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$2.08B	USD	3 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$210.00M	USD	3 Qtrs
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.11B	USD	3 Qtrs
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$1.37B	USD	3 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$438.00M	USD	3 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$406.00M	USD	3 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$880.00M	USD	3 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$169.00M	USD	3 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-34.00M	USD	3 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-59.00M	USD	3 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$5.00M	USD	3 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$56.00M	USD	3 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$925.00M	USD	3 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.79B	USD	3 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$1.72B	USD	3 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.99B	USD	3 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$96.00M	USD	3 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-262.00M	USD	3 Qtrs
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$22.00M	USD	3 Qtrs
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$52.00M	USD	3 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-14.00M	USD	3 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-13.00M	USD	3 Qtrs
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$4.43B	USD	3 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.69B	USD	3 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.85B	USD	3 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-107.00M	USD	3 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.00M	USD	3 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$912.00M	USD	3 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-541.00M	USD	3 Qtrs
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.24B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.88B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.24B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.88B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.12B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$1.34B	USD	Point-in-time

Stockholders Equity 31 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.93B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.13B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-959.00M	USD	3 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-281.00M	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$269.00M	USD	3 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-360.00M	USD	1 Quarter
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	3 Qtrs
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	1 Quarter
Issuance of shares, value	`StockIssuedDuringPeriodValueNewIssues`	-	USD	3 Qtrs
Issuance of shares, shares	`StockIssuedDuringPeriodSharesNewIssues`	-	shares	1 Quarter
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$2.00M	USD	1 Quarter
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$6.00M	USD	3 Qtrs
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$2.00M	USD	3 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$99.00M	USD	3 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$44.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$120.00M	USD	3 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$35.00M	USD	1 Quarter
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$8.00M	USD	3 Qtrs
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$2.00M	USD	3 Qtrs
Other	`OtherEquity`	$-8.00M	USD	3 Qtrs
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$14.93B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.13B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time

Comprehensive Income 33 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-307.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-1.08B	USD	3 Qtrs
Net income (loss)	`ProfitLoss`	$-197.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$771.00M	USD	3 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-138.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-105.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-577.00M	USD	3 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-5.00M	USD	3 Qtrs
Unrealized gain from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-124.00M	USD	3 Qtrs
Unrealized gain from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-19.00M	USD	1 Quarter
Unrealized gain from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-75.00M	USD	3 Qtrs
Unrealized gain from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-87.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-2.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.00M	USD	3 Qtrs
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	3 Qtrs
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$1.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-84.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-502.00M	USD	3 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-53.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$117.00M	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-959.00M	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-281.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$269.00M	USD	3 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-360.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$20.00M	USD	3 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$56.00M	USD	3 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-26.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$7.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-1.01B	USD	3 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-255.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-367.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$249.00M	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.